Mauna Kea Technologies closes $30 million financing round

February 6, 2008, Paris, France--Mauna Kea Technologies, a leader in in-vivo cellular imaging, has closed a $30 million financing round led by U.S.-based Psilos Group. Mauna Kea Technologies will use the proceeds to expand commercialization of its Cellvizio technology in the US and Europe, as well as to advance additional clinical applications of the platform.

"This financing will enable us to expand our U.S. presence and advance our clinical program to validate Cellvizio's utility in improving the diagnosis and treatment of disease found in the esophagus, colon, stomach, bile duct as well as the distal lungs, " said Sacha Loiseau, Ph.D., founder, president, and CEO of Mauna Kea Technologies. "We are pleased to have attracted world-caliber investors like Psilos and look forward to working with them as we continue to penetrate the GI and pulmonology markets and expand into additional markets in the future."

Founded in 2000, Mauna Kea Technologies develops and markets Cellvizio, a fundamentally new imaging approach which improves patient care by eliminating the need for unnecessary biopsies and enhances the diagnosis of a broad range of diseases via in vivo cellular imaging.

With over $500 million under management, Psilos Group is a leading healthcare private equity firm with offices in New York, the San Francisco Bay Area, and Santa Fe. David Eichler and Albert Waxman of Psilos will both join Mauna Kea Technologies' board. France-based Seventure also participated in this funding round in addition to existing investor Creadev. RBC Capital Markets acted as the exclusive agent for this private placement.

"We believe that Cellvizio represents a revolutionary advance in diagnostic imaging that has the potential to change the way physicians diagnose and treat a broad range of diseases," said Psilos Group Managing Member, David Eichler. "Sacha Loiseau has built a strong management team, and we look forward to helping them take the company to the next level of commercial development."

Mauna Kea also announced that it has changed the name of its U.S. operations to Cellvizio Inc. to strengthen brand awareness.

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

Single-photon counting camera for FLIM by Photonis

The Imaging Photon Camera has utility in fast imaging under low-light conditions, such as in fluorescence lifetime imaging microscopy.

FDA authorizes emergency use of Zika virus molecular detection assay

The xMAP MultiFLEX Zika RNA assay combines optofluidics and digital signal processing to detect Zika virus in vitro.

'Lab on a stick' test optically and rapidly detects antibiotic resistance

A point-of-care test, based on the dipstick method, can rapidly detect bacterial resistance to antibiotics in urine.

Merz acquires laser tattoo removal device maker ON Light Sciences

Merz North America has acquired ON Light Sciences, which develops technologies to enhance laser-based dermatology procedures.


Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...



Twitter- BioOptics World

Copyright © 2007-2016. PennWell Corporation, Tulsa, OK. All Rights Reserved.PRIVACY POLICY | TERMS AND CONDITIONS